Selinexor治疗多发性骨髓瘤的整合安全性特征:437例临床试验患者的经验
本文综述了437例接受Selinexor治疗的多发性骨髓瘤患者的临床试验安全性数据,分析了不良事件的发生动力学及支持治疗措施的效果。Selinexor主要不良事件多发生在治疗前8周内,可逆且对支持治疗有响应。
要点
- Selinexor的不良事件主要发生在治疗前8周内,且可逆。
- 血小板和中性粒细胞在第一周期内下降,于28-42天达最低点。
- 胃肠道反应最常见于治疗前1-2周,可用止吐药和止泻药管理。
核心结论
- Selinexor具有明确的不良反应,主要发生在治疗前8周内,可逆且对支持治疗有响应。
研究设计与样本
- 综述437例接受Selinexor治疗的多发性骨髓瘤患者的临床试验数据,评估不良事件动力学及支持治疗措施的影响。
主要发现
- Selinexor在第一治疗周期内降低血小板和中性粒细胞,最低点出现在28至42天之间。
- 胃肠道副作用(恶心、呕吐、腹泻)最常见于治疗前1-2周。
- 乏力、食欲下降、低钠血症等主要体质性副作用可通过相应药物管理。
关键数值与推荐
- 血小板输注和血小板生成素受体激动剂可有效治疗血小板减少,粒细胞集落刺激因子可有效缓解中性粒细胞减少。
- 恶心可用5-HT3拮抗剂联合神经激肽1受体拮抗剂、奥氮平或大麻素类缓解。
- 腹泻可用洛哌丁胺和次水杨酸铋改善。
- 乏力可用哌甲酯管理,食欲下降可用甲地孕酮、大麻素类或奥氮平管理。
- 低钠血症对补钠治疗高度敏感。
临床怎么用
- 临床应密切监测Selinexor治疗前8周内的不良反应,并积极采用支持治疗措施管理血小板减少、中性粒细胞减少、胃肠道反应及体质性副作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Selinexor is an oral, small molecule inhibitor of the nuclear export protein exportin 1 with demonstrated activity in hematologic and solid malignancies. Side effects associated with selinexor include nausea, vomiting, fatigue, diarrhea, decreased appetite, weight loss, thrombocytopenia, neutropenia, and hyponatremia. We reviewed 437 patients with multiple myeloma treated with selinexor and assessed the kinetics of adverse events and impact of supportive care measures. Selinexor reduced both platelets and neutrophils over the first cycle of treatment and reached a nadir between 28 and 42 days. Platelet transfusions and thrombopoietin receptor agonists were effective at treating thrombocytopenia, and granulocyte colony stimulating factors were effective at resolving neutropenia. The onset of gastrointestinal side effects (nausea, vomiting, and diarrhea) was most common during the first 1-2 weeks of treatment. Nausea could be mitigated with 5-HT3 antagonists and either neurokinin 1 receptor antagonists, olanzapine, or cannbainoids. Loperamide and bismuth subsalicylate ameliorated diarrhea. The primary constitutional side effects of fatigue and decreased appetite could be managed with methylphenidate, megestrol, cannabinoids or olanzapine, respectively. Hyponatremia was highly responsive to sodium replacement. Selinexor has well-established adverse effects that mainly occur within the first 8 weeks of treatment, are reversible, and respond to supportive care.
引用
- Gavriatopoulou M, Chari A, Chen C, et al. Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. Leukemia. 2020. PMID: 32094461. doi:10.1038/s41375-020-0756-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。